Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

Leukemia. 2019 Apr;33(4):1047-1051. doi: 10.1038/s41375-018-0320-9. Epub 2019 Jan 10.

A Dodero^#¹, A Guidetti^#^{2

3}, A Tucci⁴, F Barretta⁵, M Novo⁶, L Devizzi¹, A Re⁴, A Passi⁴, A Pellegrinelli⁷, G Pruneri^{8

7}, R Miceli⁵, A Testi⁷, M Pennisi¹, M C Di Chio¹, P Matteucci¹, C Carniti¹, F Facchetti⁹, G Rossi⁴, P Corradini^{1

8}

¹ Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
² Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [email protected].
³ Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. [email protected].
⁴ Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
⁵ Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁶ Department of Hematology, Azienda Ospedaliero Universitaria Citta' della Salute e della Scienza di Torino, Torino, Italy.
⁷ Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁸ Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
⁹ Department of Pathology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.

^# Contributed equally.

No abstract available

Publication types